These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20532509)

  • 1. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
    Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
    Garaventa A; Luksch R; Lo Piccolo MS; Cavadini E; Montaldo PG; Pizzitola MR; Boni L; Ponzoni M; Decensi A; De Bernardi B; Bellani FF; Formelli F
    Clin Cancer Res; 2003 Jun; 9(6):2032-9. PubMed ID: 12796365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
    Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
    Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
    Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
    Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
    ; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
    J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
    Cooper JP; Reynolds CP; Cho H; Kang MH
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
    Lewis KC; Hochadel JF
    Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
    Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
    Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.
    Baglietto L; Torrisi R; Arena G; Tosetti F; Gonzaga AG; Pasquetti W; Robertson C; Decensi A
    Cancer Detect Prev; 2000; 24(4):369-75. PubMed ID: 11059568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
    Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
    J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations.
    Formelli F; Clerici M; Campa T; Di Mauro MG; Magni A; Mascotti G; Moglia D; De Palo G; Costa A; Veronesi U
    J Clin Oncol; 1993 Oct; 11(10):2036-42. PubMed ID: 8410127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
    Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
    Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.
    Torrisi R; Parodi S; Fontana V; Rondanina G; Formelli F; Costa A; Boccardo F; Decensi A
    Cancer Epidemiol Biomarkers Prev; 1994 Sep; 3(6):507-10. PubMed ID: 8000302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
    Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
    Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma kinetics of oral retinol in cancer patients.
    Goodman GE; Alberts DS; Peng YM; Beaudry J; Leigh SA; Moon TE
    Cancer Treat Rep; 1984 Sep; 68(9):1125-33. PubMed ID: 6478452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.